Tesaro Inc

Tesaro — Investor Presentation (January 2014)

27 slides from Tesaro's investor presentation, Jan 8, 2014

  1. Slide 1: Corporate Presentation January 2014

    Corporate Presentation January 2014

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are forward-looking statements reflecting the current beliefs and expectations of management. Forward-looking statements are sometimes identified by words such as “plan,” “may,

  3. Slide 3: A Balanced Portfolio of Product Candidates

    A/C: anthracycline/cyclophosphamide MEC: Moderately emetogenic chemotherapy HEC: Highly emetogenic chemotherapy NSCLC: Non-small cell lung cancer * In collaboration with SARC, the Sarcoma Alliance for Research through Collaboration A Balanced Portfolio of Product Candidates Compound Indication Pre-c

  4. Slide 4: Rolapitant: NK-1 receptor antagonist for CINV

    A Potent and Selective NK-1 Receptor Antagonist (RA) with an Extended Half-Life Completing Phase 3 for the Prevention of Chemotherapy-Induced Nausea & Vomiting (CINV)

  5. Slide 5: Rolapitant key highlights

    Established CINV prevention guidelines support significant unmet need and additional NK-1 RA utilization Two Phase 3 trials each successfully achieved primary endpoint Differentiated on convenience, safety factors and market access strategy Oral and IV formulations allow full market access Lack of C

  6. Slide 6: Despite Available Therapies, Significant Unmet Need Remains

    1For selected patients as appropriate 2J Support Oncol 2004;2(suppl 1):1-12 HCPs: Healthcare Providers Despite Available Therapies, Significant Unmet Need Remains Start before chemotherapy Serotonin (5-HT3) receptor antagonist AND Steroid AND Neurokinin 1 antagonist NCCN Guidelines® Version 1.2013 A

  7. Slide 7: Favorable Pharmacokinetics and Pharmacodynamics: Extended Half-Life and Receptor Occupancy

    Favorable Pharmacokinetics and Pharmacodynamics: Extended Half-Life and Brain Receptor Occupancy Plasma half-life of ~180 hours Nearly 100% bioavailable High affinity for human NK-1 receptor (Ki = 0.7 nM) Greater than 1,000-fold more selective for the human NK-1 receptor vs. other targets PET scan 5

  8. Slide 8: Rolapitant Pivotal Program Design

    Rolapitant Pivotal Program Design Protection from Delayed CINV Successfully Demonstrated in Two Completed Phase 3 Trials; Safety Profile Consistent with Earlier Trials Phase 3 in MEC Completed 1,369 patients enrolled ~50% received A/C for breast cancer 5-HT3 RA + dexamethasone vs. 200mg rolapitant +

  9. Slide 9: Pivotal MEC Efficacy Results

    MEC: Moderately emetogenic chemotherapy 1 p<0.05 for rolapitant 2 p<0.05 (unadjusted) for rolapitant Caution should be used in making cross study comparisons. Pivotal MEC Efficacy Results Rolapitant Netupitant Aprepitant Complete Response (CR) No emesis No use of rescue Delayed (24 to 120 hours)1 –

  10. Slide 10: Rolapitant Has a Low Potential for CYP3A4-Mediated Drug Interactions

    Source: Aprepitant prescribing information; Helsinn Healthcare poster presentation 1 Ther Clin Risk Manag. 2005 March; 1(1): 3–13 Rolapitant Has a Low Potential for CYP3A4-Mediated Drug Interactions CYP3A4 Substrate Examples Anti-infectives: clarithromycin, erythromycin, ketoconozole Benzodiazepines

  11. Slide 11: $1.5B U.S. Market Opportunity for NK-1 RAs

    HEC: highly emetogenic chemotherapy MEC: moderately emetogenic chemotherapy A/C: anthracycline/cyclophosphamide $1.5B U.S. Market Opportunity for NK-1 RAs Annual U.S. Opportunity: 5 Million “Day 1” Chemotherapy Administrations Cisplatin-Based Regimens (HEC) A/C-based Treatments for Breast Cancer & C

  12. Slide 12: Our Opportunity: 5 Million Day One Doses Annually in the U.S.

    1 As reported by IMS National Sales Perspective Dollar figures reflect current NK-1 RA pricing of ~$300/cycle Our Opportunity: 5 Million “Day One” Doses Annually in the U.S. Significant Revenue Potential from Targeted Markets Rolapitant Potential Share: 25% 50% 75% Eligible Chemotherapy Initiations1

  13. Slide 13: Proven Commercial Strategy in CINV

    Proven Commercial Strategy in CINV Key Success Factors 1 3 2 4

  14. Slide 14: Niraparib: PARP Inhibitor in Phase 3

    A Potentially First and Best-in-Class PARP Inhibitor in Phase 3 for Ovarian and Breast Cancers

  15. Slide 15: Niraparib: Overview

    Phase 3 dose of 300mg daily was well characterized in Phase 1 Compelling response rates and durations of response in highly pre-treated populations Clinical and genetic enrichment allow for targeted development Two Phase 3 studies ongoing in patients with ovarian and breast cancer Partnerships in pl

  16. Slide 16: Key Phase 1 Results

    HGSOC: High grade serous ovarian cancer DLT: Dose limiting toxicity Key Phase 1 Results Phase 1 RECIST Response Data Durable responses >1 year in platinum sensitive ovarian patients, regardless of gBRCAmut status 431 days in gBRCA+ patients 444 days in gBRCA- patients Heavily pre-treated patient pop

  17. Slide 17: Patient Selection and Considerations for Registration Studies

    Patient Selection Standard of Care Literature Ledermann J., et. al., N Engl J Med, 2012 Gelmon, Lancet Oncology, 2011 Tutt, Lancet, 2010 Considerations for Registration Studies Ovarian Maintenance BRCA+ Breast Cancer Treatment gBRCA+ Platinum sensitive gBRCA+ or gBRCA- gBRCA+ Watchful Waiting Chemot

  18. Slide 18: Ovarian Cancer Phase 3 Trial Design

    Ovarian Cancer Phase 3 Trial Design gBRCAmut Endpoint Assessment Niraparib 300mg Placebo Non-gBRCAmut Endpoint Assessment Niraparib 300mg Placebo Response to Platinum Treatment n=360 High Grade Serous Ovarian Cancer, Platinum Sensitive, Relapsed 2:1 Randomization 2:1 Randomization n=120 n=60 n=120 n

  19. Slide 19: Breast Cancer Phase 3 Trial Design

    Breast Cancer Phase 3 Trial Design gBRCAmut, Advanced/Metastatic Breast Cancer (n=306) Up to Two Prior Treatments for Advanced/Metastatic Disease, Including Anthracycline/Taxane 2:1 Randomization 300mg Niraparib Investigator Choice: Eribulin, Capecitabine, Gemcitabine or Vinorelbine PFS >95% power t

  20. Slide 20: Significant Market Opportunities in Ovarian and Breast Cancer

    Significant Market Opportunities in Ovarian and Breast Cancer United States ~10,000 eligible ovarian cancer patients ~10,000 eligible breast cancer patients Europe ~10,000 eligible ovarian cancer patients ~10,000 eligible breast cancer patients Market Opportunity Exceeds $3B for First Two Indication

  21. Slide 21: Additional Potential Indications

    SARC: Sarcoma Alliance for Research through Collaboration Additional Potential Indications Platinum sensitivity Small Cell Lung BRCA, ATM mutations Gastric ERCC-1 mutations Non-Small Cell Lung Front-line indications Breast & Ovarian HR deficiency in 20–25% ETS gene fusions (TMPR552-ERG; 50% of prost

  22. Slide 22: TSR-011 is a Potent ALK Inhibitor

    z A potentially best-in-class, targeted approach to treating certain cancer sub-populations, including NSCLC Highly selective, oral compound Potent inhibitor of both ALK and TRK TRK gene rearrangements have been found in several tumor types, including NSCLC, AML, colorectal and papillary thyroid can

  23. Slide 23: TSR-011: Significant Response and Stable Disease in Phase 1

    All three evaluable ALK+ NSCLC patients remain on study (as of 19 Dec 2013): One RECIST Partial Response (PR) Two Non-RECIST PRs (investigator assessed) Long-term SD observed in papillary thyroid, pancreatic cancer and colorectal cancer patients without ALK expression DLT was ECG changes at 480 mg,

  24. Slide 24: Example of a Non-RECIST Response to TSR-011

    Example of a Non-RECIST Response to TSR-011 Screening Visit: ALK+ NSCLC, progressed after 7.5 months on crizotinib Extensive tumor involvement of the right lung: lung consolidated with tumor After 4 Cycles of TSR-011: Significant reduction of tumor burden with less consolidation Clinical improvement

  25. Slide 25: TESARO is Positioned for Success

    WW: Worldwide ALKi: ALK-inhibitor KOL: key opinion leader TESARO is Positioned for Success Cash and equivalents of $156M as of 9/30/2013 Average quarterly cash utilization of $20M to $25M Well Capitalized >30 collective years of commercial, development and regulatory experience in oncology Relations

  26. Slide 26: Anticipated Near-term Milestones

    Complete final Phase 3 trial of rolapitant Advance rolapitant IV clinical program Present data at ASCO, MASCC, and ESMO Present full rolapitant pivotal data set at a 2014 medical meeting Submit NDA for rolapitant to the U.S. FDA in mid-2014 Continue to enroll niraparib Phase 3 NOVA and BRAVO trials

  27. Slide 27: Corporate Presentation January 2014

    Corporate Presentation January 2014

TESARO — Investor Presentation (January 2014) on 6ix